Melatonin in clinical oncology

Neuroendocrinology Letters

Volumn 23, Issue SUPPL. 1, 2002, Pages 30-38

  Bartsch, Christian ^a   Bartsch, Hella ^a   Karasek, Michal ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Analysis; Cancer patients; Melatonin; Treatment

Indexed keywords

INTERFERON; INTERLEUKIN 2; MELATONIN; MELATONIN DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HORMONE RELEASE; HORMONE URINE LEVEL; HUMAN; HYPOTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; PINEAL BODY; QUALITY OF LIFE; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 0036265096     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Role of pinealectomy on Walker 256 carcinoma in rats
2. Relationships between the pineal gland and the mitotic activity of some tissues
3. Effect of melatonin on experimental tumors under different photo-periods and times of administration
4. Differential effect of melatonin on early and advanced passages of a DMBA-induced mammary carcinoma in the female rat
5. Neuroendocrine aspects of neoplastic growth: A review
6. The modulation of melatonin in tumor-bearing animals: Underlying mechanisms and possible significance for prognosis
7. Anti-tumor activity of the pineal gland: Effects of unidentified substances versus the effect of melatonin
8. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay
9. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer
10. Plasma melatonin and the hormone-dependency of human breast cancer
11. Urinary melatonin levels in human breast cancer patients
12. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors
13. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism
14. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumour-size
15. 24-h-Melatonin-Serumprofile bei Mammakarzinom-Patientinnen im Vergleich zu einer tumorfreien Kontrollgruppe
16. 6-sulphatoxymelatonin production in breast cancer patients
17. Melatonin and human cancer
18. Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status
19. Is the pineal gland involved in the pathogenesis of endometrial carcinoma
20. Serum melatonin circadian profile in women with adenocarcinoma of uterine corpus
21. Serum melatonin circadian profiles in women suffering from the genital tract cancers
22. A significant correlation between melatonin deficiency and endometrial cancer
23. Circadian rhythms of serum melatonin, prolactin and growth hormone in patients with benign and malignant tumours of the prostate and in non-tumour controls
24. Evidence for modulation of melatonin secretion in men with benign and malignant tumours of the prostate: Relationship with the pituitary hormones
25. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: Evidence for reduced pineal activity and relevance of urinary determinations
26. Prostate cancer and tumour stage-dependent circadian neuroendocrine disturbances
27. Melatonin secretion in oncological patients: Current results and methodological considerations
28. Melatonin rhythms in prostate cancer patients: Effect of operation and hormone treatment
29. Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumour growth?
30. Melatonin in cancer with extra-reproductive location
31. Nocturnal rhythm of melatonin secretion in strumectomized patients with normal thyrotropin blood levels and recurrent non-toxic benign thyroid nodules
32. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients
33. Diurnal excretion of melatonin in cancer of the stomach and large intestine
34. Plasma melatonin levels in patients suffering from colorectal carcinoma
35. Urinary 6-sulfatoxymelatonin levels in osteosarcoma: A case-control study
36. A clinical study of the pineal gland activity in oncologic patients
37. Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis
38. Growth and new growth: Environmental carcinogens in the process of ontogeny
39. Clinical study of melatonin in untreatable advanced cancer patients
40. Endocrine and immune effects of melatonin therapy in metastatic cancer patients
41. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies
42. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin
43. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone
44. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast cancer patients
45. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
46. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms
47. A randomised study with subcutaneous low-dose interleukin-2 alone vs. interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma
48. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour
49. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates
50. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced nonsmall cell lung cancer
51. Efficacy of melatonin in the immunotherapy of cancer using interleukin-2
52. Melatonin therapy of advanced human malignant melanoma
53. Treatment of human metastatic malignant melanoma with high dose oral melatonin
54. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study
55. Melatonin cancer therapy
56. Effects of melatonin administration in advanced breast cancer patients - Preliminary report
57. Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion
58. Melatonin: A sleep-promoting hormone
59. Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients